# Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

> **NCT00346827** · PHASE2,PHASE3 · COMPLETED · sponsor: **Britannia Pharmaceuticals Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Apomorphine Nasal Powder

## Key facts

- **NCT ID:** NCT00346827
- **Lead sponsor:** Britannia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00346827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00346827, "Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00346827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*